Background for journalists & clinicians
Referenced material on persistent side effects from finasteride, SSRIs and isotretinoin — with sources you can check for yourself.
Background briefing
Six referenced starting points for understanding these conditions.
What the conditions are
PFS, PSSD and PAS describe sexual, cognitive and emotional symptoms that continue after finasteride, SSRIs or isotretinoin have been discontinued. They affect a minority of patients, but for those affected the symptoms can be long-lasting.
Source: PubMedRegulatory recognition
The FDA required finasteride labelling to note that sexual side effects may persist after discontinuation (2011). The EMA required the same for SSRIs and SNRIs (2019). MedDRA added Post-Finasteride Syndrome as a coded term in 2021.
Source: EMA PRAC, FDA label historyAn awareness gap, not a dispute
A 2024 Harvard Medical School survey found that 18% of dermatologists considered persistent effects possible. These conditions are uncommon and are not yet a routine part of medical training — which is where better information helps most.
Source: Harvard Medical School, 2024What the biology suggests
A peer-reviewed study found expression differences across 3,764 genes in PFS patients, and animal research has identified distinct brain alterations — findings that are difficult to attribute to expectation alone.
Source: Journal of Sexual Medicine, 2021Reports on record
WHO VigiBase holds 21,287 finasteride adverse event reports from 153 countries; FDA FAERS holds 11,557. These databases record reports, not confirmed causal links — but they show the scale of what is being reported.
Source: WHO VigiBase, FDA FAERSWhy the numbers are likely low
Adverse event reporting is voluntary, and the FDA estimates that only 1–10% of reactions are ever reported. Establishing the true prevalence of these conditions remains an open research question.
Source: FDA pharmacovigilance guidanceKey databases & sources
FDA FAERS Dashboard
Search adverse event reports for finasteride, SSRIs, and isotretinoin.
PubMed — PFS Research
Peer-reviewed publications on Post-Finasteride Syndrome.
BMJ — Study 329 Re-analysis
An independent re-analysis of paroxetine trial data under the RIAT initiative.
WHO VigiBase
The global database of individual case safety reports, covering 153 countries.
Expert contacts
Researchers and advocates available for interview.
Prof. Roberto Melcangi
University of Milan. Leading PFS researcher. Neurosteroid pathways, epigenetics, gut-brain axis.
Dr. David Healy
RxISK.org. Psychiatrist and pharmacovigilance expert. PSSD characterization and diagnostic criteria.
PFS Foundation
The leading PFS advocacy organisation. Can connect you with patients willing to speak on record.
Media enquiries
Contact us at media@sidefxhub.com for interviews, data requests, or to be connected with patients and researchers.
SIDEfxHUB — UK Registered Charity #1203385